Elicio Therapeutics (ELTX) Profit After Tax (2020 - 2026)

Elicio Therapeutics (ELTX) has 7 years of Profit After Tax data on file, last reported at -$11.8 million in Q1 2026.

• Quarterly Profit After Tax fell 5.73% year-over-year to -$11.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$40.2 million (up 21.49% YoY) and the FY2025 annual result came in at -$39.5 million, up 23.84% from the prior year.
• Profit After Tax retreated to -$11.8 million in Q1 2026, from -$7.8 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$6.7 million in Q4 2022 to a low of -$18.8 million in Q3 2024.
• A 5-year average of -$9.8 million and a median of -$9.1 million in 2023 frame the typical range for Profit After Tax.
• The widest YoY moves for Profit After Tax: up 80.76% in 2022, down 144.76% in 2022.
• Tracing ELTX's Profit After Tax over 5 years: stood at -$6.7 million in 2022, then slumped by 37.51% to -$9.1 million in 2023, then tumbled by 53.12% to -$14.0 million in 2024, then jumped by 44.2% to -$7.8 million in 2025, then tumbled by 51.24% to -$11.8 million in 2026.
• The last three Profit After Tax figures came in at -$11.8 million (Q1 2026), -$7.8 million (Q4 2025), and -$10.0 million (Q3 2025), per Business Quant data.